Scientists hunt for bacterial clues to personalize lung cancer care
NCT ID NCT04711330
Summary
This study aims to learn if the collection of bacteria in a patient's body (the microbiome) can help predict who will benefit from a specific lung cancer immunotherapy drug called durvalumab, or who might experience severe side effects. Researchers will collect stool, throat swabs, and breath samples from about 126 patients with advanced lung cancer who are receiving this standard treatment. The goal is to find non-invasive 'biomarkers' that could one day help doctors better personalize treatment plans.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ingel Demedts
Roeselare, B8800, Belgium
-
Kristof Cuppens
Hasselt, Flanders, 3500, Belgium
-
Leiden University Medical center
Leiden, 2333ZA, Netherlands
-
Lynn Decoster
Turnhout, B2300, Belgium
-
Netherlands Cancer Institute
Amsterdam, 1066CX, Netherlands
-
Piet Verkouteren
Aalst, B-9300, Belgium
Conditions
Explore the condition pages connected to this study.